Research programme: interleukin-11 derivatives - Bolder BioTechnology

Drug Profile

Research programme: interleukin-11 derivatives - Bolder BioTechnology

Alternative Names: BBT 030; BBT 045; BBT 059

Latest Information Update: 19 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bolder BioTechnology
  • Class Interleukins
  • Mechanism of Action Interleukin 11 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombocytopenia

Most Recent Events

  • 19 Aug 2010 Bolder BioTechnology receives SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) for an interleukin-11 analog development in Thrombocytopenia
  • 07 Nov 2006 Animal efficacy studies in progress
  • 16 Dec 2002 Preclinical trials in Thrombocytopenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top